Amgen/Chugai EPO ruling
Executive Summary
Will be reviewed by the full International Trade Commission. The ITC commissioners will evaluate the Jan. 10 initial determination by ITC Administrative Law Judge Sydney Harris that would allow Chugai to continue to import erythropoietin (EPO) into the U.S. The Commission has until April 10 to make a final decision to uphold or overturn the ALJ's ruling.
You may also be interested in...
'Touchless Plants' To Virtually Trained Workforces - Indian Cos Share Digitalization Tips
Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.
More IVD Mergers: Agilent Buys Resolution, Hologic Acquires Diagenode
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.
Merck & Co. Will Manufacture J&J Vaccine, Other COVID-19 Medicines Under BARDA Deal
Broader than initially reported, Merck & Co.’s agreement with BARDA extends beyond J&J’s recently authorized vaccine to other COVID-19 vaccines and therapeutics as needed.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: